It should be a given fact for an industry so important to the world as pharmaceutical, but it’s still reassuring to see it announced publicly.

The European Medicines Agency (EMA) has this week reaffirmed that it will continue its long-standing commitment to independence and transparency in its evaluation of COVID-19 treatments and vaccines, as it does for all other medicines.

In an open letter to the European Ombudsman, Emily O’Reilly, it explains that since the start of the pandemic it “has been working with EU National Competent Authorities and the European Commission to harness expertise from across the EU”.

Among the exceptional measures being taken by the EMA, one notable step is compressing a multi-year process into a mere several months, by fully mobilizing resources to expedite their advice & evaluation processes. All while maintaining their safety and efficacy standards, and applying tested independence and transparency rules.

With potential new vaccines making front-page news almost daily, it’s reassuring to hear that tried and tested measures are being used to ensure that the EMA’s recommendations are driven only by science and public health needs, and not by any other interests.

Follow us on LinkedIn for more industry news and opinions.

Additional News

  • 19 December 2023

    Happy new year 2024

    As we bid farewell to 2023, it's time to express our deepest gratitude for the collaboration.

  • 4 December 2023

    Our new clinical unit in Ostrava comes to life

    It's a great pleasure to announce that after two years of hard work, the brand-new clinical unit in Ostrava with 36-beds capacity has been opened.

  • 3 October 2023

    Meet us at the heart of Pharma, CPHI 2023

    Quinta-Analytica is attending CPHI 2023 in Barcelona